Fortis Healthcare Limited

rs,

ement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement prlnciples laid down in Indian

6.5 billion

ngement, tortious interference with contracts, etc. and Party has claimed damages in excess of USO 6.5 billion against all the defendants. Company has made disclosure about this case to stock exchange. It has

1 %

ue"), subject to approval of the shareholders and other regulatory approvals which constituted 31 .1 % share capital of the Company. The shareholders of the Company approved the Preferential Issue by r

77%

sequent to which the shareholding of the erstwhile Promoter Group in the Company was reduced to 0. 77% terms of agreements dated September 30, 201 7, FHsL assigned the outstanding ICDs to a third part

71%

bsidiary (i.e. Escorts Heart Institute and Research Centre Limited ("EHIRC L")), purchased further 71% equity interest in Fortis Healthstaff Limited("Healthstaff) al an aggregate consideration of Rupee

29%

le promoter group company. EHIRCL also could not directly takeover the Joan , as EHIRCL (l"lolding 29%) could not have taken over the burden of the entire debt of Healthstaff. Therefore, this transacti

71 %

althstaff. Therefore, this transaction was in a way to help the erstwhile promoter group companies (71 % shareholders) to avoid making payment for its share. and place EHIRCL in a situation where rt woul

51 %

the Company through its subsidiary (i.e. Fortis Hospitals Limited (" FHsL ")) . purchased further 51 % equity interest in Fortis Emergency Services Limited (FESL) al an aggregate consideration of Rupee

49%

erstwhile promoter group company. FHsL also could not directly takeover the loan, as FHsL (holding 49%) could not have taken over the burden of the entire debt of FESL. Therefore, this transaction was

100%

ar 2014-15, the Company through its subsidiary (i.e. Fortis Hospitals Limited (" FHsL")), acquired 100% stake in Birdie & Birdie Realtors Pvt; Ltd . ("Birdie") from certain persons related to the erstwh

14%

e erstwhile promoters, wherein Rupees 12,275 lacs were pa id towards !CDs at a rate of interest of 14% per annum and Rupees 7,725 lacs were paid for the shares acquired. The total enterprise value of B

10%

March 31, 2018, investments held in the Global Dynamic Opportunity Fund were sold at a discount of 10%. (ix) (D) There is no further finding in additional procedures/enquiries by independent exper

“In the aforesaid context, proper and sufficient care has also been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities on a going forward basis.”

“Based on the external legal counsel advice, the Company believes that EHIRCL will be able to suitably defend the termination of lease deeds and allotment letters and accordingly considers that no adjustments are required to the unaudited Consolidated Financial Results.”

“the significant amount of dividend in the year ended March 31 , 2020 was largely on account of a one-off transaction which led to dividend payment and the Company does not expect dividend of such a significant amount to be recurring in future.”

“The Board has also noted and confirmed that such dividend does not represent income from ordinary activities of the Company and that the Company does not intend to carry on the business as an NBFC .”

“and does not intend to, carry on the business as an NBFC and hence keeping in view the objective behind the test, its registration as a NBFC should not be required .”

“and that the Company has represented to the RBI that it does not presently or in future intend to undertake the business of non-banking financial institution.”

“Going forward , the actlial impact of the Covid-19 pandemic may still be different from that what has been estimated.”

“The accounting effect to these agreements will be given in subsequent period Date: August 5, 2022 Place· Bengaluru Fo r and o n behalf of the Board of Directors Dr.”

“By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

“The shares of FHIPL will be cancelled without payment or other consideration.”

Cash

2

Parent

1

Subsidiaries

1

Joint ventures

1

Associates

1

For further details please contact

1

Details of the Transferee Entity

1

Details of the Transferor Entity

1

Subsidiaries

(I) Escorts Heart Institute and Research Centre limited ("EHIRCL") (Ii) Fortis Hospitals Limited {Iii) Fortis Asia Healthcare Pte Limited (iv) Fortis Healthcare International Limited ISl&C...(•p-..i.lllffl.,•• ... ,,.,_,_,,o IIA61Ull<-led-151~C...LIP(•Lffittd U.tbl:,r, P,ort.-.o.'lipwlchU, Rq,<t,_ 1to.Mll llllh,~holf1<1 l"""O<t•bo< 1•. lOU 14th float (f""1 11 aw.,..,., Noni\ C w,na. hf'K.CI n P•\ •• Nf'll(O Ce-mH w., .. ,.1,,.. .. ~ ... ..,,Goft4-((.,,1 - ' - l PanA 1 nf 4 B S R & Co. LLP (v) Fortis Global Healthcare (Mauritius) Limited {vi) Fortis Malar Hospitals Llmfted (vii) Malar Stars Medicare Limited (viii) Fortis Health Starf Limited (ix) Fortis Cancer Care Limited (x) Fortis La Femme Limited (xi) Fortis Health Management (East) Limited (xii) Hiranandanl Healthcare Private Limited (xiii) SRL Limited (xiv) SRL Diagnostics Private Limited (xv) SRL Reach Limited (xvi) SRL Diagnostics FZ- LLC (xvii) Fortis Healthcare International Pte Limited ('FHIPL') (xviii) Birdie and Birdie Real

Joint ventures

(i) Fortis Cauvery (ii) Fortis C- Doc Healthcare Limited (iii) SRL Diagnostics (Nepal) Private Limited B S R & Co. LLP

Associates

(I) Lanka Hospitals Corporate Pie (II) THR Infrastructure Pte Ltd (iii) RHT Health Trust S. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. 6. Based on our review conducted and procedures performed as stated In paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted In India, has not disclosed the Information required to be disclosed In terms of

Cash

Domestic, 36.1% Pvt Corps, 1.0% Govt & PSUs, 8.9% International , 3.7% CGHS, 2.9% ECHS, 3.9% Pvt Corps, 0.9% Govt & PSUs, 10.2% International , 7.1% CGHS, 3.2% ECHS, 6.0% HOSPITAL BUSINESS PERFORMANCE Most of the facilities across the network continue to witness a strong traction in revenues Revenue Q1FY22 Q1FY23 169 131 135 108 110 81 100 76 100 82 96 71 89 89 64 57 55 43 45 44 FMRI Mohali BG Road FEHI Shalimar Bagh Noida Mulund Anandpur Jaipur Faridabad Revenue Q4FY22 Q1FY23 169 145 135 111 110 95 100 85 100 85 96 82 89 82 53 57 55 43 41 44 FMRI Mohali BG Road FEHI Shalimar Bagh Noida Mulund Anandpur Jaipur Faridabad All figures in INR Crs. HOSPITAL MARGIN MATRIX 3 2 Y F 1 Q 2 2 Y F EBITDA No of Facilities Revenue Contribution Operational beds ARPOB (INR Cr) Occupancy >25% 20% - 25% 15% - 20% 10% - 15% <10% 4 4 5 4 5 43% 13% 20% 14% 10% 1,210 561 910 514 706 2.53 1.70 1.54 2.07 1.44 70% 66% 71% 65% 50% EBITDA No of Facilities Revenue Contribution Operational beds ARPOB (INR Cr) Occup

For further details please contact

Anurag Kalra / Gaurav Chugh Investor Relations +91-9810109253 / 9958588900 Fortis Healthcare Limited Ajey Maharaj Corporate Communication +91-9871798573 Fortis Healthcare Limited 4/4 Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel Fax Emergency Email Website : 0124 492 1033 : 0124 492 1041 : 105010 : secretarial@fortishealthcare.com : www.fortishealthcare.com Annexure Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 S. No. Particulars 1 Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc. . Description

Details of the Transferee Entity

Fortis Asia Healthcare Pte Limited (‘FAHPL’), incorporated in Singapore, is a wholly-owned subsidiary of Escorts Heart Institute and Research Centre Limited (‘EHIRCL’) which in turn is a wholly-owned subsidiary of Fortis Healthcare Limited (the Company).